SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 58.17+3.9%Dec 4 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (2312)12/15/2000 10:33:59 PM
From: rkrw  Read Replies (1) of 52153
 
In my experience it was very unusual for MAXM to have gotten as far as filing for approval based on subset analysis. More typical is calling the trial a failure but shining light on the positive subset, regrouping, and running a pivotal on the subset. This is not uncommon, although rarely met with success.

The difference in this case was that MAXM claimed or tried to claim the FDA signed off on the subset investigation all along. The FDA didn't quite see it the same way.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News